Drug maker Genentech, developer of the brand-name rituximab, Rituxan, has announced that the FDA has accepted a supplemental Biologics License Application for the drug’s first proposed pediatric indication: 2 rare forms of vasculitis.
Drug maker Genentech, developer of the brand-name rituximab, Rituxan, has announced that the FDA has accepted a supplemental Biologics License Application (sBLA) for the drug’s first proposed pediatric indication: 2 rare forms of vasculitis.
The BLA, which was granted priority review, seeks approval for rituximab in combination with glucocorticoids for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children aged 2 years or more. GPA and MPA are rare diseases that cause inflammation of small blood vessels, impacting blood flow and leading to organ damage.
Cases of pediatric-onset GPA and MPA are rare, and are associated with severe, sometimes life-threatening symptoms, and to date, there are no approved therapies to treat children with these disorders.
“We are committed to delivering new treatment options for rare diseases, such as pediatric GPA and MPA…,” said Sandra Horning, MD, chief medical officer and head of global product development at Genentech, in a statement. “We will continue to work closely with the FDA to bring Rituxan to children with these [2] serious and potentially life-threatening diseases.”
The sBLA relies on data from the PePRS study, a phase 2a open-label, single-arm study of rituximab in pediatric patients with newly diagnosed or relapsing GPA or MPA.1 The study in 25 patients at 11 centers included 4 rituximab infusions and a 6-month remission induction phase. In total, 56% of patients achieved remission by month 6, and 100% achieved remission by month 18. All patients in the study had 1 or more adverse event, with infusion reactions being the most commonly reported.
While both forms of vasculitis are rare, and cases in children are rarer still, the new indication could be another means by which Genentech can defend some sales of its brand-name drug against upcoming biosimilar competition.
The FDA has approved 1 biosimilar rituximab, Truxima, but due to issues related to intellectual property, its developers, Celltrion and Teva, sought approval only in malignant indications, and none in other approved Rituxan indications such as rheumatoid arthritis, in which the biosimilar was also studied.
Reference
1. Brogan P, Cleary G, Hersch AO, et al. Pediatric open-label clinical study of rituximab for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Presented at: the American College of Rheumatology 2018 Annual Meeting; October 19-24, 2018; Chicago, Illinois. Abstract L04.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.